Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 141

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 141
---
ended and Restated Bylaws contains provisions that are intended to enhance the likelihood of continuity and stability in the composition of our board of directors and that could make it more difficult to acquire control of us by means of a tender offer, open market purchases, a proxy contest or otherwise. A description of these provisions is set forth below.

Delaware Anti-Takeover Law

We are subject to Section 203 of the Delaware General Corporation Law. Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:

| ● | prior                                                                                                                                 
 to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction 
 which resulted in the stockholder becoming an interested stockholder;                                                                 |
| ● | upon                                                                                                                                  
 consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned 
 at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding specified shares;    
 or                                                                                                                                    |
| ● | at                                                                                                                                    
 or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an     
 annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding 
 voting stock which is not owned by the interested stockholder.                                                                        |

| 100 |

Section 203 defines a “business combination” to include:

| ● | any                                                                                                                                   
 merger or consolidation involving the corporation and the interested stockholder;                                                     |
| ● | any                                                                                                                                   
 sale, lease, exchange, mortgage, pledge, transfer or other disposition of 10% or more of the assets of the corporation to or with     
 the interested stockholder;                                                                                                           |
| ● | subject                                                                                                                               
 to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the     
 interested stockholder;                                                                                                               |
| ● | subject                                                                                                                               
 to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of    
 any class or series of the corporation beneficially owned by the interested stockholder; or                                           |
| ● | the                                                                                                                                   
 receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits